376 related articles for article (PubMed ID: 29471874)
1. Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment.
MaassenVanDenBrink A; Terwindt GM; van den Maagdenberg AMJM
Genome Med; 2018 Feb; 10(1):10. PubMed ID: 29471874
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic antibodies against CGRP or its receptor.
Bigal ME; Walter S; Rapoport AM
Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
Bigal ME; Walter S; Rapoport AM
Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
[TBL] [Abstract][Full Text] [Related]
4. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
5. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
6. Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape.
Fiala JL; Lowery D
Nat Rev Drug Discov; 2016 Jan; 15(1):8-9. PubMed ID: 26669672
[No Abstract] [Full Text] [Related]
7. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
Charles A; Pozo-Rosich P
Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
[TBL] [Abstract][Full Text] [Related]
8. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
Yuan H; Lauritsen CG; Kaiser EA; Silberstein SD
BioDrugs; 2017 Dec; 31(6):487-501. PubMed ID: 29116598
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin gene-related peptide (CGRP): a new target for migraine.
Russo AF
Annu Rev Pharmacol Toxicol; 2015; 55():533-52. PubMed ID: 25340934
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
Pellesi L; Guerzoni S; Pini LA
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
[TBL] [Abstract][Full Text] [Related]
11. CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?
Majima M; Ito Y; Hosono K; Amano H
Trends Pharmacol Sci; 2019 Jan; 40(1):11-21. PubMed ID: 30502971
[TBL] [Abstract][Full Text] [Related]
12. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
13. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
14. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
Taylor FR
Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
[TBL] [Abstract][Full Text] [Related]
15. [Novel migraine treatment with CGRP-related monoclonal antibodies].
Shibata M
Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.
Wattiez AS; Sowers LP; Russo AF
Expert Opin Ther Targets; 2020 Feb; 24(2):91-100. PubMed ID: 32003253
[No Abstract] [Full Text] [Related]
17. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice.
Tiseo C; Ornello R; Pistoia F; Sacco S
J Headache Pain; 2019 May; 20(1):49. PubMed ID: 31060490
[TBL] [Abstract][Full Text] [Related]
18. New migraine therapies promise prevention: A new generation of drugs could avert migraine attacks rather than merely relieve symptoms.
Hunter P
EMBO Rep; 2016 Jun; 17(6):797-9. PubMed ID: 27154401
[TBL] [Abstract][Full Text] [Related]
19. A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine.
Reuter U
Headache; 2018 May; 58 Suppl 1():48-59. PubMed ID: 29697156
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.
Ong JJY; Wei DY; Goadsby PJ
Drugs; 2018 Mar; 78(4):411-437. PubMed ID: 29396834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
